Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs iShares MSCI South Korea ETF (EWY) Price & Performance

BioNTech SE - ADRTrade
iShares MSCI South Korea ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs iShares MSCI South Korea ETF — how do they compare? BioNTech SE - ADR trades at $90.28 (market cap $22.86B), while iShares MSCI South Korea ETF trades at $173.79. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXEWY
Market Cap
$22.86B
Sector
HealthBroad Market / Factor
52-Week High
$119.34$219.20
52-Week Low
$83.89$70.65
Enterprise Value
$6.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

iShares MSCI South Korea ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY